• Cytochalasin D for Actin-Dependent Uptake Assays

  2026-08-21

  Cytochalasin D converts actin dynamics into a controllable experimental variable for nanoparticle uptake, cytoskeletal imaging, cell-cycle, and invasion assays. This workflow connects a defined actin perturbation to the 2024 human corneal epithelial cell study while emphasizing dose control, orthogonal readouts, and interpretation limits.

• CX-5461 Drives Mitotic Catastrophe in Cervical Cancer

  2026-08-20

  A June 2026 Biochemical Pharmacology study shows that CX-5461 suppresses cervical cancer cell growth by coupling DNA damage with aberrant mitotic entry and mitotic catastrophe. The findings also indicate that Pol I inhibition can increase cisplatin sensitivity, supporting further investigation in resistant or recurrent disease models.

• Cyclic Pifithrin-α hydrobromide in p53 assays

  2026-08-20

  Cyclic Pifithrin-α hydrobromide provides a reversible chemical approach to dissect p53-dependent transactivation, apoptosis, and DNA-damage responses. This guide translates its established cancer-cell use cases into rigorous assay workflows while clearly separating validated evidence from exploratory applications in neuroinflammation and pain biology.

• GW4064: Non-Steroidal FXR Agonist

  2026-08-19

  GW4064 is a potent, selective non-steroidal FXR agonist for studying bile acid, cholesterol, and triglyceride regulation. Its activity in receptor and cell assays supports FXR activation in metabolic research, while limited aqueous solubility, light sensitivity, and context-specific fibrosis evidence restrict its use to research applications.

• CX-5461: Mapping Ribosome-Stress Responses

  2026-08-19

  CX-5461 is an RNA polymerase I inhibitor that connects rRNA transcriptional stress with DNA damage, mitotic catastrophe, senescence, and autophagy. This article offers a response-state framework for interpreting assays and designing translational cancer research experiments.

• Cisplatin (CDDP): Mechanism and Research Workflow

  2026-08-18

  Cisplatin, also called CDDP, is a platinum-based DNA crosslinking agent that disrupts replication and transcription and can activate apoptosis. This article connects its molecular mechanism with apoptosis assay design, xenograft research, renal-toxicity modeling, and chemotherapy resistance studies.

• Cepharanthine and EGFR Signaling in Nasopharyngeal Cancer

  2026-08-18

  This study combines network pharmacology, molecular docking, and experimental validation to investigate cepharanthine (CEP) in nasopharyngeal carcinoma. Its findings connect CEP activity with suppression of the EGFR/PI3K/AKT/mTOR axis and provide a mechanistic framework for evaluating CEP in future cancer research, while leaving questions about pharmacokinetics, target causality, and clinical translation unresolved.

• Gentamycin Sulfate for Reliable Cell Assays

  2026-08-17

  This scenario-based guide explains how Gentamycin Sulfate, SKU A2514, can support contamination control, bacterial infection models, and antibiotic-resistance experiments without obscuring mammalian cell-assay interpretation. It covers formulation, compatibility, workflow controls, resistance data, and practical supplier-selection criteria.

• Cy5-UTP for Fluorescent RNA Probe Synthesis

  2026-08-17

  Cy5-UTP, also called Cyanine 5-uridine triphosphate, is a fluorescent UTP analog for T7 in vitro transcription RNA labeling. Its 650/670 nm excitation and emission maxima support direct detection of labeled RNA for RNA probe synthesis, FISH, and dual-color expression arrays.

• TaSERL2–TaBZR2 Control of Wheat Heat Tolerance

  2026-08-16

  The reference study identifies a TaSERL2–TaBZR2 regulatory module that connects receptor-like kinase phosphorylation with wheat thermotolerance. TaBZR2 promotes heat-stress tolerance, whereas TaSERL2 suppresses it by reducing TaBZR2 stability and transcriptional activity; heat stress weakens this inhibition by lowering phosphorylation.

• SMYD2 Inhibition in Cisplatin-Induced Renal Fibrosis

  2026-08-15

  The reference study identifies SMYD2 as a pharmacologically tractable regulator of cisplatin-induced chronic kidney disease, linking its inhibition with reduced renal fibrosis, epithelial–mesenchymal transition, and inflammation. By evaluating AZ505 and LLY507 in an injury model and tubular epithelial cells, the work provides a mechanistic foundation for studying SMYD2–Smad3/STAT3 signaling in renal pathology.

• RITA (NSC 652287) Assay Workflow Guide

  2026-08-14

  RITA (NSC 652287) combines MDM2-p53 pathway interrogation with DNA cross-linking activity, making it useful for mechanism-aware viability and apoptosis workflows. This guide shows how to separate growth arrest from true cell killing, optimize dosing, and extend findings from renal carcinoma research into tumor xenograft model planning.

• H. pylori, HNF4A, and Gastric Cancer Epigenetics

  2026-08-14

  The reference study identifies promoter hypermethylation of HNF4A as a mechanistic link between Helicobacter pylori infection, loss of gastric epithelial polarity, and activation of TGFβ-associated EMT signaling. Its integrated clinical, single-cell, cellular, and in vivo evidence supports HNF4A silencing as a functional driver of gastric tumorigenesis and metastasis, while suggesting a testable framework for tumor suppressor gene reactivation studies.

• Cisplatin Workflows for Sensitivity and Apoptosis

  2026-08-13

  Build reproducible CDDP experiments around DNA damage, apoptosis, and resistance rather than relying on a single viability endpoint. APExBIO’s Cisplatin supports dose-response, combination, and mechanistic workflows spanning cancer research and translational tumor models.

• Nanoparticle Uptake by Corneal Cells: Size and Chemistry

  2026-08-13

  The reference study establishes a controlled PLGA nanoparticle platform for separating the effects of particle size and surface chemistry on uptake by human corneal epithelial cells. Its results identify energy-dependent endocytosis, particularly macropinocytosis and caveolae-mediated uptake, as the principal routes under the tested in vitro conditions and provide design guidance for topical ocular delivery.

16940 records 1/1130 page Next 12345 下5页 Last page